Egypt: Curative liver resection (LR) can be safely carried out in carefully selected elderly patients with hepatocellular ...

Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

A novel liver-on-a-chip model can be used to study immune cell interactions in liver cancer and test promising new therapies.

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Transarterial chemoembolization (TACE) is currently the most common approach for the management of hepatocellular carcinoma (HCC) without curative options. TACE consists of the injection of ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

A recent study found that patients with chronic liver disease integrated regular healthcare visits into their daily routines ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

In this study, women with hepatocellular carcinoma were less likely to receive a deceased-donor liver transplant and more likely to die while wait-listed than men with hepatocellular carcinoma; these ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...